These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1428 related items for PubMed ID: 25192851

  • 21. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
    Lebrun-Frénay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, Vermersch P, Papeix C, Thouvenot E, Labauge P, Durand-Dubief F, Efendi H, Le Page E, Terzi M, Derache N, Bourre B, Hoepner R, Karabudak R, De Seze J, Ciron J, Clavelou P, Wiertlewski S, Turan OF, Yucear N, Cohen M, Azevedo C, Kantarci OH, Okuda DT, Pelletier D, TERIS Study Group.
    JAMA Neurol; 2023 Oct 01; 80(10):1080-1088. PubMed ID: 37603328
    [Abstract] [Full Text] [Related]

  • 22. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.
    Neurology; 2016 Mar 08; 86(10):920-30. PubMed ID: 26865517
    [Abstract] [Full Text] [Related]

  • 23. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Mar 08; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 24. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M.
    Mult Scler; 2024 Jun 08; 30(7):833-842. PubMed ID: 38619037
    [Abstract] [Full Text] [Related]

  • 25. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS, Teriflunomide Multiple Sclerosis Trial Group.
    Mult Scler; 2012 Nov 08; 18(11):1625-32. PubMed ID: 22723573
    [Abstract] [Full Text] [Related]

  • 26. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S, RENEW Study Investigators.
    Lancet Neurol; 2017 Mar 08; 16(3):189-199. PubMed ID: 28229892
    [Abstract] [Full Text] [Related]

  • 27. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators.
    Lancet Neurol; 2018 May 08; 17(5):405-415. PubMed ID: 29545067
    [Abstract] [Full Text] [Related]

  • 28. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foà R.
    Lancet Haematol; 2017 Nov 08; 4(11):e534-e543. PubMed ID: 28958469
    [Abstract] [Full Text] [Related]

  • 29. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul 08; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 30. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 08; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
    Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, Ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Moran C, Flynn PD, Michell AW, Franklin RJM, Chandran S, Altmann DR, Chard DT, Connick P, Coles AJ.
    Lancet Neurol; 2021 Sep 08; 20(9):709-720. PubMed ID: 34418398
    [Abstract] [Full Text] [Related]

  • 32. Teriflunomide for multiple sclerosis in real-world setting.
    Elkjaer ML, Molnar T, Illes Z.
    Acta Neurol Scand; 2017 Nov 08; 136(5):447-453. PubMed ID: 28321835
    [Abstract] [Full Text] [Related]

  • 33. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators.
    N Engl J Med; 2022 Aug 25; 387(8):704-714. PubMed ID: 36001711
    [Abstract] [Full Text] [Related]

  • 34. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL.
    Lancet Neurol; 2020 Dec 25; 19(12):998-1009. PubMed ID: 33129442
    [Abstract] [Full Text] [Related]

  • 35. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
    Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024 Dec 25; 124(4):86-96. PubMed ID: 38676683
    [Abstract] [Full Text] [Related]

  • 36. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE, DISCOMS investigators.
    Lancet Neurol; 2023 Jul 25; 22(7):568-577. PubMed ID: 37353277
    [Abstract] [Full Text] [Related]

  • 37. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.
    Lancet Neurol; 2013 Aug 25; 12(8):756-67. PubMed ID: 23764350
    [Abstract] [Full Text] [Related]

  • 38. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K, Rózsa C, Vécsei L.
    Ideggyogy Sz; 2015 Mar 30; 68(3-4):79-87. PubMed ID: 26434194
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI, SYNERGY study investigators.
    Lancet Neurol; 2019 Sep 30; 18(9):845-856. PubMed ID: 31285147
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov 30; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 72.